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for infectious disease. To overcome pre-existing immunity to
commonly used human adenovirus serotype 5 (Ad5), vectors
based on rare species or non-human Ads are being developed.
However, these vectors often exhibit reduced potency compared
with Ad5, necessitating the use of innovative approaches to
augment the immunogenicity of the encoded antigen (Ag). To
achieve this, we engineered model Ag, enhanced green ﬂuores-
cent protein (EGFP), for targeting to the surface of host-derived
extracellular vesicles (EVs), namely exosomes. Exosomes are
nano-sized EVs that play important roles in cell-to-cell commu-
nication and in regulating immune responses. Directed target-
ing of Ag to the surface of EVs/exosomes is achieved by “exo-
some display,” through fusion of Ag to the C1C2 domain of
lactadherin, a protein highly enriched in exosomes. Herein,
we engineered chimpanzee adenovirus ChAdOx1 and Ad5-
based vaccines encoding EGFP, or EGFP targeted to EVs
(EGFP_C1C2), and compared vaccine immunogenicity in
mice. We determined that exosome display substantially in-
creases Ag-speciﬁc humoral immunity following intramuscular
and intranasal vaccination, improving the immunological
potency of both ChAdOx1 and Ad5. We propose that this Ag-
engineering approach could increase the immunogenicity of
diverse Ad vectors that exhibit desirablemanufacturing charac-
teristics, but currently lack the potency of Ad5.Received 26 July 2019; accepted 12 December 2019;
https://doi.org/10.1016/j.omtm.2019.12.003.
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The family Adenoviridae comprises double-stranded DNA viruses
that include human species A to G, within the genusMastadenovirus.
To date, more than 100 human adenoviruses and more than 200 ad-
enoviruses derived from non-human primates (NHPs) have been
identiﬁed, the latter of which largely cluster phylogenetically with hu-
man adenoviral (Ad) species.1–4 In the past decade, non-replicating
Ad vectors have shown signiﬁcant promise as vaccine delivery
vehicles.5 Ads have an excellent safety proﬁle following intramuscular
(i.m.),6,7, intranasal (i.n.),8 or oral9,10 delivery in healthy adults, in-
fants,11 and neonates,12,13 the elderly,7 and the immunocompro-108 Molecular Therapy: Methods & Clinical Development Vol. 16 March
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desirable vaccine manufacturing attributes, with an estimated pro-
duction time from selection to formulation and product ﬁlling of
11–13 weeks.15 In addition, procedures for clinical development
such as regulatory guidance release testing for Ad vectors (e.g., vac-
cine potency, vector stability) already exist for the US Food and
Drug Administration (FDA) and European Medicines Agency
(EMA). Furthermore, Ad vaccine formulations maintain stability
over time and are thermostable with minimal losses to immunoge-
nicity under cold-chain free conditions.16,17 Collectively, these char-
acteristics highlight the suitability of Ad vaccines for stockpiling,
rapid response, and global preparedness efforts against inﬂuenza vi-
rus5,16,17 and other emerging pathogens.
Ad vaccines are known to elicit robust and sustained frequencies of
antigen (Ag)-speciﬁc CD8+ T cell responses toward encoded trans-
gene Ag in animal models.18–20 As a result, vaccines based on Ad vec-
tors have been evaluated in clinical trials for infectious diseases,
including inﬂuenza,6,7 respiratory syncytial virus (RSV),8 hepatitis
C virus (HCV),21 and human immunodeﬁciency virus (HIV).22
Although human adenovirus serotype 5 (Ad5) is widely considered
to be the most immunogenic Ad vector, high seroprevalence from
natural infection may limit vaccine efﬁcacy in humans.23,24 As a
result, investigators have moved toward the development and evalu-
ation of rare species human Ad vectors or those derived from NHPs.
The use of rare species or non-human Ads, as well as ﬁber-pseudo-
typed or hexon chimeric Ad vectors, can circumvent pre-existing im-
munity to Ad5.23–28 Although selected rare or non-human vectors
display comparable immunogenicity to Ad5,28–30 a large proportion
of alternative Ad vectors have substantially reduced immunoge-
nicity,24,30 when compared to Ad5.28 Therefore, efforts to optimize2020 ª 2019 The Authors.
://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. In Vitro Confirmation of Exosome Display Targeting of Model Ag to Exosomes
(A) Schematic diagram showing expression plasmid design. Enhanced green fluorescent protein (EGFP) was engineered into pcDNA3.1SSmut_C1C2 to generate
pcDNA3.1SSmut-EGFP_C1C2 (EGFP_C1C2) or pcDNA3.1SSmut-EGFPD (EGFPD), respectively. (B and C) Following transfection of Expi293F cells with EGFPD (B) or
EGFP_C1C2 (C), exosomes were purified by ultracentrifugation (100,000 g) and size exclusion chromatography (SEC). ELISAs using 20 mL of each SEC fraction confirmed
enrichment of exosome markers, tetraspanins CD9, CD63, and CD81 on expected fractions (exosomes are 8–13) for EGFPD and EGFP_C1C2, and EGFP on the surface of
(legend continued on next page)
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Molecular Therapy: Methods & Clinical Developmentand increase the inherent immunogenicity of Ad vectors, which have
otherwise desirable characteristics (i.e., high titer growth), will be
important in enabling cost-effective production and dose-sparing us-
age of commercially manufactured Ad vaccines.
A chimpanzee Ad vector, ChAdOx1, expressing highly conserved
internal inﬂuenza Ags (nucleoprotein [NP] and matrix protein-1
[M1]) has undergone phase I clinical evaluation in humans as a uni-
versal inﬂuenza virus vaccine candidate, aimed at boosting Ag-spe-
ciﬁc cytotoxic T-lymphocyte (CTL) responses.6,7 In agreement with
the known capability of Ad vaccines to induce excellent CD8+ T cell
responses, ChAdOx1-NP+M1 has been found to elicit robust CD8+
T cells in healthy adults and older adults.6,7 However, induction of
Ag-speciﬁc antibody (Ab) responses following ChAdOx1 vaccina-
tion in mice is impaired when compared with Ad5.1,31 Therefore,
in this study, we used a molecular adjuvant approach called “exo-
some display” to improve the immunogenicity of Ag delivered by
ChAdOx1.32
Exosomes are extracellular vesicles (EVs) released by almost all cells,
which play critical roles in cell-to-cell communication and in the
regulation of immune responses.33–35 In 1996, it was discovered
that exosomes could present Ag to T cells and thereby modulate im-
mune responses.36 As such, there is potential for manipulating their
communications with the immune system to improve vaccine re-
sponses. Exosome display is the directed targeting of Ags to exo-
somes,37 achieved by fusion of Ag to a protein domain enriched on
exosomes, such as the C1C2 domain from lactadherin.38,39 In ani-
mals, exosome display has been shown to increase Ab responses to
cancer vaccine Ags 100- to 500-fold.40,41 Therefore, we reasoned
that this approach could be exploited to increase the immunogenicity
of Ag delivered by ChAdOx1 (referred to as ChAd throughout the ﬁg-
ures), so that it exhibits a more robust immunogenic proﬁle. Using
enhanced green ﬂuorescent protein (EGFP) as a model Ag, we em-
ployed this molecular adjuvant approach to tether EGFP_C1C2
fusion protein to the surface of host-derived EVs, including exo-
somes, comparing the immunogenicity of ChAdOx1 to Ad5 following
i.m. and i.n. administration in mice.
RESULTS
Fusion of EGFP to the C1C2 Domain of Lactadherin by Exosome
Display Successfully Targets Ag to the Surface of EVs/
Exosomes In Vitro
Prior to engineering Ad vector genomes expressing EV-targeted Ag
expression cassettes, we wanted to demonstrate in vitro proof ofEGFP_C1C2-transfected cells only. (D) SEC fractions enriched for CD9, CD63, and CD
confirm 150-nm size and concentration. The mode value for size is shown, which is t
purified exosomes to confirm the presence of tetraspanins CD9, CD63, and CD81 an
transfected cells only. Data shown represent background subtraction of matched isoty
Du145 cells (provided by Prof. A Clayton and Dr. J. Webber, Cardiff University, Cardiff, U
as a positive control for EGFP Ab binding. Dashed line separates exosome samples from
(CL) from the corresponding transfected cells to detect exosome-enriched endosoma
reticulum protein GRP94.
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the exosome-enriched C1C2 domain of lactadherin. We selected
monomeric EGFP as a model Ag and generated C1C2-fusion and
matched expression plasmids without C1C2 (EGFPD), on a
pcDNA3.1 backbone (Figure 1A). pcDNA3.1-EGFP_C1C2 or non-
targeted pcDNA3.1-EGFPD was transfected into Expi293F suspen-
sion cells, equivalent EGFP expression was conﬁrmed by western
blot (Figure S1A) and EGFP ﬂuorescence-activated cell sorting
(FACS) (Table S1), and exosomes were puriﬁed from the supernatant
(SN) by ultracentrifugation (UC) at 100,000  g, followed by a com-
mercial size-exclusion chromatography (SEC) approach, validated for
puriﬁcation of exosomes.42
Tetraspanins such as CD9, CD63, and CD81 are enriched in subpop-
ulations of exosomes43 and can therefore be used to validate exo-
some-isolation methods.44 In this study, the successful isolation of
exosomes in elution fractions 8–13 was conﬁrmed by ELISA for tet-
raspanins CD9/CD63 and CD81 (Figures 1B and 1C). Analysis of
identical fractions conﬁrmed that exosomes puriﬁed from
EGFP_C1C2-transfected cells had EGFP on the surface (8–13; Fig-
ure 1C), whereas exosomes puriﬁed from the SN of cells transfected
with plasmids expressing EGFPD did not (8–13; Figure 1B). Frac-
tions 8–13, corresponding with tetraspanin marker enrichment,
were pooled, and puriﬁed exosomes were subsequently evaluated
by nanoparticle tracking analysis (NTA) to conﬁrm the particle titer
and 150-nm size (Figure 1D).44 We further validated the pooled,
puriﬁed exosomes by performing ELISAs for tetraspanins CD9/
CD63 and CD81 in parallel with EGFP, again conﬁrming that only
exosomes derived from the SN of cells transfected with pcDNA3.1-
EGFP_C1C2 had EGFP on the exosome surface (Figure 1E). In
addition to conﬁrming the puriﬁcation of EVs with exosomal-like
properties, we further validated these preparations by performing
western blots for exosome-associated endosomal protein, ALIX,
and the exosome-excluded endoplasmic reticulum marker GRP94
(Figure 1F). As expected, we detected the presence of ALIX in our
puriﬁed exosome samples, but not in the cleared cell lysate (CL).
In contrast, GRP94 was strongly detected in the cell lysate but was
hardly detectable on exosomes, in agreement with previous studies.43
In summary, we conﬁrmed that fusion of model Ag to the membrane-
associated C1C2 domain of lactadherin could successfully tether
EGFP to the surface of EVs, including exosomes, in vitro. These
ﬁndings supported the engineering of C1C2 fusion Ag expression cas-
settes into non-replicating Ad vectors for subsequent in vivo expres-
sion of exosome display EGFP following vaccination.81 were validated using nanoparticle tracking analysis (NTA: Malvern Panalytical) to
he size in nanometers of the majority of particles. (E) ELISA on 1 mg/well of pooled,
d the presence of EGFP on the surface of exosomes purified from EGFP_C1C2-
pe control Abs. Positive controls for tetraspanins included exosomes purified from
K). Wells coated with 1 mg/mL recombinant EGFP protein (Abcam, USA) were used
control samples. (F) Western blot on purified exosomes (Exo) and cleared cell lysate
l protein ALIX and to show minimal detection of exosome-excluded endoplasmic
2020
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Infection of A549 Cells with an Ad Vector Expressing EGFP_C1C2
DNAencodingEGFP_C1C2 andnon-targeted control EGFPDwas en-
gineered into a non-replicating Ad5 or ChAd vectored vaccine to test
whether the exosome display approach could improve transgene-spe-
ciﬁc immunogenicity in vivo. We ﬁrst conﬁrmed that expression levels
of EGFPD and EGFP_C1C2 were comparable following transduction
of A549 and Chinese hamster ovary (CHO)-coxsackie and adenovirus
receptor (CAR) cells with both Ad vectors (Figures S1B–S1E). To sup-
port our proof-of-concept data where we conﬁrmed successful target-
ing of EGFP_C1C2 but not EGFPD to the surface of exosomes in vitro
using accepted EV puriﬁcation and validationmethodology (Figure 1),
we subsequently demonstrated that EGFP could be targeted to the
surface of EVs derived from A549 cells following expression of
EGFP_C1C2 by an Ad vaccine in vitro (Figure S2). A549 cells were in-
fected with each Ad vector, and using precipitation-based puriﬁcation,
EVswere crudely puriﬁed from theSNofA549 cells grown in exosome-
depleted fetal bovine serum (FBS) 72 h post-infection. When we per-
formed validation ELISAs on the EV pellet to detect CD9/CD63 and
CD81 in parallel with EGFP, we conﬁrmed that only EVs precipitated
from the SN of A549 cells infected with Ad5-EGFP_C1C2, but not
Ad5-EGFPD, had EGFP on the surface of EVs. We were unable to
detect an EGFP signal for the ChAd vector (data not shown); however,
this would be consistent with its very low transduction efﬁciency in
A549 cells relative to Ad5 (see Figures S1B and S1C). Although the
ChAd vector efﬁciently infects hamster CHO-CAR cells (see Figures
S1D and S1E), our validation ELISAs for CD9/CD63 and CD81 are
for exosomes derived fromhuman cells, and theAbs are speciﬁc for hu-
man tetraspanins. Therefore, we were unable to conﬁrm these ﬁndings
for the ChAd vector in vitro.
It is important to highlight that there are several technical challenges
and caveats to using an in vitro system to demonstrate exosome
display and release by Ad-infected cells. In order to purify sufﬁcient
quantities of exosomes for high-quality analysis that adhere to the
minimal guidelines for the International Society for Extracellular
Vesicles (ISEV),44,45 we puriﬁed exosomes from 100 to 250 mL
of serum-free Expi293F SN following transfection with our
pcDNA3.1-SS-EGFPD and EGFP_C1C2 expression constructs using
ultracentrifugation and size-exclusion chromatography (as outlined
in Figure 1). However, these large volumes would be impossible to
infect with practical quantities of puriﬁed Ad viruses (MOI of 250 in-
fectious units [IFU]/cell for 250 mL of suspension at 2  106/mL). In
addition, we cannot conﬁrm exosome display-based EGFP loading
following expression from an Ad vector using Expi293F cells because
this cell line supports the replication of E1-deleted Ad vectors, which
would confound our results. Therefore, this assay was restricted to us-
ing A549 cells grown in media containing exosome-depleted FBS in a
six-well plate format with duplicate volumes of 5 mL, resulting in very
low yield of EVs/exosomes for analysis. Finally, the precipitation-
based method used to isolate concentrated and detectable quantities
of EVs from a such a small SN sample puriﬁes a heterogeneous pop-
ulation of vesicles, including non-exosomal particles. Therefore, we
think that the transfection of Expi293F cells with pcDNA-based vec-Moleculartors expressing EGFPD or EGFP_C1C2 is a more robust and techni-
cally feasible means of demonstrating proof of concept for the success
of the exosome display approach in vitro.
Incorporation of the Exosome Display Model Ag EGFP into
Human and Non-human Ad Vaccine Vectors Results in
Increased Ag-Specific Humoral Immunity following i.m.
Vaccination in Mice
Following vaccination with non-replicating Ad5 or ChAd vectored
vaccines encoding EGFP_C1C2 and non-targeted control EGFPD,
EGFP protein should be expressed within cells infected with Ad5/
ChAd following immunization and processed via classical Ag presen-
tation pathways. However, we hypothesized that exosome-bound
EGFP_C1C2 could also be released from host cells (via natural,
endogenous exosome biogenesis pathways) and taken up by neigh-
boring Ag-presenting cells (APCs), potentially augmenting immuno-
genicity. Ad5 vaccines are well established for their ability to elicit
robust humoral immune responses directed toward encoded trans-
gene Ags.20,30,46–48 Although the ChAd vaccine used in this study
(ChAdOx1) can elicit potent T cell responses in animal models1,31,49
and humans,6,7 its ability to elicit high Ab titers in mice is impaired
when compared with Ad5.1,31 We anticipated that the presentation
of EGFP on the surface of EVs/exosomes could improve Ab responses
to this Ag when encoded within the ChAd vector. Therefore, we per-
formed a head-to-head comparison of the in vivo immunogenicity of
ChAd-EGFPD and ChAd-EGFP_C1C2, as well as Ad5-EGFPD and
Ad5-EGFP_C1C2, following i.m. or i.n. vaccination of mice.
We determined that EGFP-speciﬁc serum immunoglobulin (Ig)G Ab
responses elicited following a single i.m. vaccination with an Ad vac-
cine were greatly improved when EGFP was fused to C1C2 (Figures
2A–2D, green boxes, green circles). Surprisingly, improvements in
immunogenicity were not limited to ChAd, but were also detected
for the highly immunogenic vector Ad5 (Figures 2A–2D), with geo-
metric mean endpoint titers for Ad5-EGFP_C1C2 10-fold greater
than Ad5-EGFPD (Figure 2C, p < 0.0001). Differences in endpoint ti-
ters for ChAd were more pronounced than those observed for Ad5,
with ChAd-EGFP_C1C2 responses 400-fold greater than those
for ChAd-EGFPD (Figure 2C, p < 0.0001). These increases in immu-
nogenicity were sustained at day 28 (D28) (Figures S3A–S3D), with
geometric mean endpoint titers for Ad5-EGFP_C1C2 being 9-
fold greater than Ad5-EGFPD (Figure S3C, p = 0.0079) and 363-
fold greater for ChAd-EGFP_C1C2 compared with ChAd-EGFPD
(Figure S3C, p = 0.0079).
We also compared Ad vaccines expressing EGFPD or EGFP_C1C2 us-
ing an area under the curve (AUC) analysis (Figure 2D). We deter-
mined that AUC values were increased 10-fold for Ad5- and 817-fold
for ChAd, respectively, when EGFP was fused to C1C2 compared
with EGFPD (both p < 0.0001). These increases in immunogenicity
were again sustained atD28,withAUCvalues forAd5-EGFP_C1C2be-
ing >7-fold greater than Ad5-EGFPD and 631-fold greater for ChAd-
EGFP_C1C2 compared with ChAd-EGFPD (Figure S3D, both p =
0.0079). Although somemice in the day 14 (D14) ChAd-EGFPD groupTherapy: Methods & Clinical Development Vol. 16 March 2020 111
Figure 2. Expression of EGFP_C1C2 Fusion Ag by an
Ad Vaccine Results in Improved Ag-Specific Humoral
Immune Responses in Serum following i.m. Delivery
in Mice
(A) Mice were vaccinated i.m. with 1 108 IFU Ad5-EGFPD
(gray box), Ad5-EGFP_C1C2 (green box), or PBS (naive) in a
final volume of 50 mL. Two weeks later, anti-EGFP IgG re-
sponses in sera were measured by ELISA using plates
coated with 1 mg/mL recombinant EGFP protein. (B) Mice
were vaccinated i.m. with 1  108 IFU ChAd-EGFPD (gray
circle) or ChAd-EGFP_C1C2 (green circle), and ELISA as-
says were performed exactly as described in (A). Data show
mean ± SEM (n = 10 mice/group) of duplicates, and plots
are representative of two to three technical repeats and two
independent repeat experiments (combined) with n =
5/group. (C) Endpoint titers represent the reciprocal dilution
of the x intercept with the baseline (set to the mean plus
3 times the standard deviation [SD] of the mean of naive
controls). Solid line indicates the geometric mean. Dashed
line indicates starting dilution of sera (1:100), and therefore
the lower limit of detection for the assay. Values below this
line are estimated at half the input dilution (i.e., 1:50 dilution
is estimated to represent the endpoint). (D) The area under
the curve (AUC) represents the total peak area calculated
from ELISA values, where the baseline was set to the mean
plus 3 times the SD of the mean of naive controls. Samples
where no AUC could be calculated were set arbitrarily to a
value of 1.0. Line indicates the geometric mean. Statistical
significance was determined using a non-parametric Mann-
Whitney test. ****p < 0.0001. (E–J) Ag-specific isotype
subclass Abs IgG1, IgG2a and IgG2b were also measured by
ELISA using a starting dilution of 1:33. (E) Ad5 serum IgG1.
(F) ChAd serum IgG1. (G) Ad5 serum IgG2a. (H) ChAd serum
IgG2a. (I) Ad5 serum IgG2b. (J) ChAd serum IgG2b. Data
show mean ± SEM (n = 5 mice/group) representative of two
to three technical repeats performed in biological dupli-
cates. Note that where SEM error bars are not visible, this is
due to the error bar being shorter than the size of the
symbol.
Molecular Therapy: Methods & Clinical Developmenthad IgG endpoint titers and AUC values that were below the limit of
detection, the same mice had robust splenic T cell responses to EGFP
(see below), suggesting that the lack of IgG responsewas not due to inef-
fective i.m. vaccination. Data presented in Figures 2A–2D and S3A–
S3D agree with earlier ﬁndings regarding the reduced immunogenicity112 Molecular Therapy: Methods & Clinical Development Vol. 16 March 2020of ChAd relative to Ad5,1,31 with minimal EGFP-
speciﬁc Ab responses detected following i.m. vacci-
nation with ChAd-EGFPD (gray circles).
Delivery of Exosome Display EGFP by Ad5 or
ChAd Vaccine Vectors Leads to Increases in
Ag-Specific IgG Subclass Abs following i.m.
Vaccination in Mice
In the disease context, it is well established that
speciﬁc Ab isotypes, and IgG subclasses, elicited
through vaccination using different vaccine plat-
forms can contribute to protective efﬁcacy. This
can be due to the induction of protective Abswhich preferentially engage speciﬁc Fcg receptors (FcgRs) and
mediate effector function-based clearance and subsequent protection
from pathogen challenge, independently of neutralizing Abs.50–53 In
mice, such Abs include IgG isotype subclasses that have high-afﬁnity
interactions with activating FcgRs, namely IgG2a > IgG2b > IgG1.
54,55
www.moleculartherapy.orgAlthough the vaccines described herein express a model Ag EGFP, for
which no protective function can be measured, we wanted to investi-
gate whether the exosome display molecular adjuvant approach could
broaden or skew the proﬁle of Ag-speciﬁc IgG subclasses elicited by
vaccination, and to investigate whether the route of vaccine adminis-
tration impacts this.
We performed EGFP-speciﬁc IgG subclass ELISAs, detecting mouse
IgG1, IgG2a, and IgG2b Abs in the serum (Figures 2E–2J). Similar ELI-
SAs were performed for isotypes IgG3, IgA, and IgM, but responses
were very low or undetectable (data not shown), in agreement with
previous studies.56 As anti-EGFP responses elicited by ChAd-EGFPD
were so low, it is difﬁcult to assess the isotype subclass distribution
(Figures 2F, 2H, and 2J). However, we determined that delivery of
EGFP_C1C2 by both Ad5 and ChAd vaccines resulted in increased
responses to EGFP across all IgG subclasses measured. There were
subtle differences in the skewing of responses between the Ad5 and
ChAd vaccines. Ad5 induced EGFP-speciﬁc responses in the order
IgG2a > IgG1 > IgG2b, whereas ChAd induced responses that were
IgG2a > IgG2b > IgG1. This differential pattern of IgG subclass skewing
for Ad5- and chimpanzee Ad-based vaccines is consistent with previ-
ous studies.46,56,57 The predominance of IgG2a responses following
i.m. vaccination was reassuring, as it suggested that fusion of a dis-
ease-speciﬁc Ag to C1C2, combined with Ad-vectored delivery,
may result in IgG responses of a Th1 phenotype. Such Abs would
preferentially interact with murine activating FcgRs and should
therefore be capable of mediating effector functions in vivo. Th1 re-
sponses have been shown to be essential for protection from viral res-
piratory pathogens in animal models,58,59 emphasizing the relevance
of this approach for vaccines for viral diseases.
Intranasal Vaccination with Human and Non-human Ad Vaccine
Vectors Expressing Exosome Display Model Ag EGFP Results in
Increased Ag-Specific Humoral Immunity in Mice
Ad vaccines are gaining interest as vaccine delivery vehicles that might
be capable of eliciting both systemic and mucosal immunity for respi-
ratory pathogens such as seasonal and pandemic inﬂuenza virus60 and
RSV.8,61Therefore,wewanted to establishwhether the exosomedisplay
molecular adjuvant approach could also increase the Ag-speciﬁc
immunogenicity of Ad5 and ChAd following i.n. vaccination in mice.
In agreement with ﬁndings following i.m. vaccination, EGFP-speciﬁc
serum IgG responses were also increased following i.n. administration
of Ad5- and ChAd- expressing EGFP-C1C2, when compared with
control EGFPD (Figures 3A and 3B). Geometric mean endpoint titers
were increased45-fold (p = 0.0001) and 30-fold (p = 0.0051) for Ad5
and ChAd, respectively, when EGFP was fused to C1C2 (Figure 3C).
Endpoint titers at D28 following i.n. immunization maintained
improvements of 21-fold for Ad5-EGFP_C1C2 compared with
Ad5-EGFPD (Figures S4A and S4C, p = 0.0079) and 65-fold for
ChAd-EGFP_C1C2 (Figures S4B and S4C, p = 0.0159). Similarly,
D14 AUC values were increased 45-fold (p = 0.0001) and 40-
fold (p = 0.0051) for Ad5/ChAd-EGFP_C1C2 compared with
EGFPD (Figure 3D). Again, AUC responses at D28 were stillMolecularincreased for Ad5-EGFP_C1C2 compared with Ad5-EGFPD (15-
fold, p = 0.0079), and responses were more pronounced for ChAd-
EGFP_C1C2, which was increased 112-fold over ChAd-EGFPD
(Figure S4D, p = 0.0079). We identiﬁed three mice in the D14 EGFPD
groups with no detectable IgG ELISA responses following i.n. vaccina-
tion, but with a detectable splenic T cell response (see below).
We also measured the IgG subclass of the EGFP-speciﬁc serum Ab
response following i.n. vaccination with Ad5 or ChAd vectors (Figures
3E–3J). Results obtained following i.n. administration of Ad vectors
expressing EGFP_C1C2 largely mirrored the subclass distribution
observed following i.m. vaccination. Again, Ad5 elicited EGFP-spe-
ciﬁc IgG responses, which were largely IgG2a > IgG1 > IgG2b, whereas
ChAd elicited responses, which were IgG2a > IgG2b > IgG1.
Exosome Display of EGFP Delivered by Ad5- or ChAd-Based
Vaccines Elicits IncreasedMucosal IgGResponses following i.n.
Vaccination in Mice
In addition to serum, we also collected bronchoalveolar lavage (BAL)
and lung tissue from mice vaccinated i.n, to quantify local humoral
and cellular immune responses to the vaccine Ag EGFP. Ag-speciﬁc
IgG responses in BAL were measured by ELISA (Figures 4A–4D).
In agreement with serum IgG responses following i.m. and i.n. vacci-
nation (see Figures 2A–2D and 3A–3D), we also detected increased
IgG responses in the BAL when EGFP was fused to C1C2. Again,
the improvement in immunogenicity was observed for both Ad5
and ChAd vectors. IgG endpoint titers were increased 42-fold for
Ad5-EGFP_C1C2 over Ad5-EGFPD (p = 0.0002), and 30-fold for
ChAd when EGFP was fused to C1C2 (p = 0.0027). When we per-
formed similar ELISAs on BAL at D28 post-immunization (Figures
S4E–S4H), geometric mean endpoint titers for Ad5-EGFP_C1C2
were still increased 11-fold when compared with Ad5-EGFPD (p =
0.0079). Ag-speciﬁc IgG responses in the BAL were also increased
20-fold at D28 for ChAd-EGFP_C1C2 compared with ChAd-EGFPD
(p = 0.0159). Similarly, AUC at D14 values were increased 63-fold
(p = 0.0002) and 47-fold (p = 0.002) for Ad5 and ChAd expressing
EGFP_C1C2 compared with EGFPD, respectively. Again, AUC
values at D28 post-immunization were 10-fold greater for Ad5-
EGFP_C1C2 compared with Ad5-EGFPD (p = 0.0079) and 32-fold
greater for ChAd-EGFP_C1C2 versus ChAd-EGFPD (p = 0.0159).
In conclusion, the exosome display molecular adjuvant approach,
achieved by fusion of EGFP to the C1C2domain of lactadherin, allowed
increases in systemic and mucosal Ag-speciﬁc IgG immune responses
elicited by ChAd and Ad5. Importantly, this approach resulted in
ChAd-EGFP_C1C2 eliciting humoral immune responses to EGFP
that were comparable to the baseline immunogenicity ofAd5 (EGFPD),
a gold-standard benchmark in the ﬁeld for Ad vector immunogenicity.
Fusion of Model Ag EGFP to C1C2 and Delivery Using Ad5/ChAd
Vaccine Vectors Does Not Negatively Impact Systemic Ag-
Specific Cellular Immunity in Mice
As Ad vectors are well established for their ability to induce potent
T cell responses to transgene Ag,20,28,30 we wanted to assess whetherTherapy: Methods & Clinical Development Vol. 16 March 2020 113
Figure 3. Expression of EGFP_C1C2 Fusion Ag by an
Ad Vaccine Results in Improved Ag-Specific
Humoral Immune Responses in Serum following i.n.
Delivery in Mice
(A) Mice were vaccinated i.n. with 1  108 IFU Ad5-
EGFPD (gray box), Ad5-EGFP_C1C2 (green box), or PBS
(naive) in a final volume of 50 mL of PBS. Two weeks later,
anti-EGFP IgG responses in sera were measured by
ELISA using plates coated with 1 mg/mL recombinant
EGFP protein. (B) Mice were vaccinated i.n. with 1  108
IFU ChAd-EGFPD (gray circle) or ChAd-EGFP_C1C2
(green circle), and assays were performed exactly as
described in (A). Data show mean ± SEM (n = 5–10 mice/
group) of duplicates and are representative of two inde-
pendent experiments (data combined), as well as tech-
nical repeats. (C) Endpoint titers represent the reciprocal
dilution of the x intercept with the baseline (set to themean
plus 3 times the standard deviation [SD] of the mean of
naive controls). Line indicates the geometric mean.
Dashed line indicates starting dilution of sera (1:100);
values below this line are estimated at half the input dilu-
tion (i.e., 1:50 dilution is estimated to represent endpoint).
Line indicates the geometric mean. (D) The area under the
curve (AUC) represents the total peak area calculated
from ELISA values, where the baseline was set to the
mean plus 3 times the SD of the mean of naive controls.
Samples where no AUC could be calculated were set
arbitrarily to a value of 1.0. Solid line indicates the geo-
metric mean. Statistical significance was determined us-
ing a non-parametric Mann-Whitney test. **p < 0.01,
***p < 0.001. (E–J) Ag-specific isotype subclass Abs IgG1,
IgG2a, and IgG2b were also measured by ELISA. (E) Ad5
serum IgG1. (F) ChAd serum IgG1. (G) Ad5 serum IgG2a.
(H) ChAd serum IgG2a. (I) Ad5 serum IgG2b. (J) ChAd
serum IgG2b. Data show mean ± SEM (n = 5–10 mice/
group) representative of two to three technical repeats
performed in biological duplicates. Note that where SEM
error bars are not visible, this is due to the error bar being
shorter than the size of the symbol.
Molecular Therapy: Methods & Clinical Developmentfusion of EGFP to the C1C2 domain affected the induction of Ag-spe-
ciﬁc cellular immune responses. We measured T cell responses in the
spleen by interferon (IFN)-g enzyme-linked immunospot (ELISpot)
following i.m. (Figures 5A and 5B) and i.n. (Figures 5C and 5D) vacci-114 Molecular Therapy: Methods & Clinical Development Vol. 16 March 2020nation with each vector, EGFPD and
EGFP_C1C2. T cell responses to the entire
EGFP peptide pool (Figures 5A and 5C) and
to the H2-Kd-restricted CD8+ T cell epitope
(Figures 5B and 5D) followed a similar trend,
and robust responses were detected for both
stimulation conditions. Following i.m. vaccina-
tion with the ChAd vaccines, we observed an in-
crease in ELISpot responses when comparing
EGFP_C1C2 with EGFPD; however, this was
not statistically signiﬁcant. Importantly, the
robust cellular immune responses associated
with Ad vectors were not impaired by targetingEGFP to the surface of EVs/exosomes for either vector, Ad5 or ChAd.
As expected, ELISpot responses in the spleen following i.n. vaccina-
tion were lower than responses detected following i.m. vaccination.
Ag-speciﬁc T cell responses to the EGFP200–208 CD8
+ T cell epitope
Figure 4. Expression of EGFP_C1C2 Fusion Ag by an
Ad Vaccine Results in Improved Ag-Specific Humoral
Immune Responses in BAL following i.n. Delivery in
Mice
(A) Mice were vaccinated i.n. with 1 108 IFU Ad5-EGFPD
(gray box), Ad5-EGFP_C1C2 (green box), or PBS (naive) in
a final volume of 50 mL of PBS. Two weeks later, anti-EGFP
IgG responses in BAL were measured by ELISA using
plates coated with 1 mg/mL recombinant EGFP protein. (B)
Mice were vaccinated i.n. with 1  108 IFU ChAd-EGFPD
(gray circle) or ChAd-EGFP_C1C2 (green circle), and as-
says were performed exactly as described in (A). Data show
mean ± SEM (n = 5–10 mice/group) representative of two
independent experiments with biological duplicates (data
combined). (C) Endpoint titers represent the reciprocal
dilution of the x intercept with the baseline (set to the mean
plus 3 times the standard deviation (SD) of the mean of
naive sera controls). Solid line indicates the geometric
mean. Dashed line indicates starting dilution of sera (1:33);
values below this line are estimated at half the input dilution
(i.e., 1:17 dilution is estimated to represent endpoint). (D)
The area under the curve (AUC) represents the total peak
area calculated from ELISA values where the baseline was
set to the mean plus 3 times the SD of the mean of naive
sera controls. Samples where no AUC could be calculated
were set arbitrarily to a value of 1.0. Statistical significance
was determined using a non-parametric Mann-Whitney
test. **p < 0.01, ***p < 0.001.
www.moleculartherapy.orgwere again increased when comparing EGFP_C1C2 with EGFPD
following delivery by the ChAd vaccine platform relative to Ad5,
although this was not statistically signiﬁcant.
Fusion of Model Ag EGFP to C1C2 Improves Local Cellular
Immunity in the Lung for ChAd but Not Ad5 following i.n.
Vaccination in Mice
As previously stated, Ad vaccines are a very attractive platform vector
for mucosal administration, particularly for vaccination against respi-
ratory pathogens.8,60,61 We conﬁrmed that targeting EGFP to the sur-
face of EVs/exosomes through fusion to the C1C2 domain of lactad-
herin could improve EGFP-speciﬁc IgG responses in the BAL
following i.n. vaccination (Figures 4A–4D). Therefore, we wanted
to assess whether T cell responses in the lung and in the BAL were
improved with the EGFP_C1C2 transgene cassette compared with
EGFPD, when delivered by Ad5 or ChAd vaccines (Figure 5E–5J).
Because the ELISpot we performed does not permit distinction be-
tween CD4+ or CD8+ T cell responses (with the exception of the
EGFP200–208 CD8
+ restricted epitope), we performed ﬂow cytometry
with intracellular cytokine staining (ICS) to phenotype cells isolated
from BAL and whole perfused lung. An example of the gating strategy
is presented in Figure S5. To allow detection of CD4+ and CD8+ T cell
responses, we stimulated cells with the entire EGFP peptide pool,
rather than the CD8+ restricted epitope. We did not detect CD4+
T cell responses (data not shown). CD8+ T cell responses in both
the lung and BAL were largely similar for Ad5, with no signiﬁcant
difference in IFN-g, tumor necrosis factor (TNF)-a or interleukin
(IL)-2 production when comparing EGFP_C1C2 and EGFPD (Fig-Molecularures 5E–5J). However, we again observed consistent trends toward
increased T cell responses with EGFP_C1C2 for ChAd, with signiﬁ-
cantly increased responses measured for TNF-a production in
CD8+ lung T cells (Figure 5G), and IFN-g production in BAL
CD8+ T cells (Figure 5H). In the lung, the TNF-a+ response from
CD8+ T cells increased 7-fold for ChAd-EGFP_C1C2 compared
with ChAd-EGFPD (p = 0.045). In the BAL, CD8+ T cells secreting
IFN-g for ChAd-EGFP_C1C2 were increased 7.8-fold (p =
0.0475) over ChAd-EGFPD.
DISCUSSION
It is well documented that pre-existing anti-vector immunity can
negatively impact the immunogenicity of Ad vaccines,25,62–64 partic-
ularly those based on common human serotypes such as Ad5. In an
effort to overcome this, there has been an expansion of interest in
recent years in developing rare species of human Ad vectors (i.e.,
Ad26),22 or vectors derived from NHPs, including chimpanzees
(i.e., ChAd68,57 ChAdOx1,32 ChAd6365). The potency of Ad-based
vectors in eliciting transgene-speciﬁc CD8+ T cell responses is well
established.20,28,30,66 However, the ability to elicit transgene-speciﬁc
responses, particularly Abs, can vary from vector to vector, or with
route of vaccine administration.56,57 This emphasizes the importance
of choosing the optimal Ad vaccine platform and vaccination regimen
for a speciﬁc disease of interest. Although selected Ad vectors display
comparable cellular or humoral immunogenicity to the gold-standard
Ad5 vector (i.e., ChAd330 or ChAd6328), the vast majority of new Ad
platforms exhibit immunological potencies that are reduced 100 to
1,000-fold relative to Ad5.28,30 The precise mechanistic factors thatTherapy: Methods & Clinical Development Vol. 16 March 2020 115
Figure 5. Ag-Specific T Cell Responses Are Not
Impaired following i.m. or i.n. Delivery of Ad Vectors
Expressing Exosome Display EGFP in Mice
(A and B) Mice were vaccinated i.m. with 1  108 IFU Ad5-
EGFPD (gray box), Ad5-EGFP_C1C2 (green box), ChAd-
EGFPD (gray circle), ChAd-EGFP_C1C2 (green circle), or
PBS (naive) in a final volume of 50 mL of PBS. Two weeks
later, anti-EGFP IFN-g+ T cell responses in the spleen were
measured by ELISpot. Splenocytes were stimulated over-
night with an EGFP peptide pool spanning the entire EGFP
Ag (EGFP PepMix) (A) or with the H2-Kd-restricted peptide
EGFP200–208 (B). Solid line indicates median (n = 5 mice/
group). (C and D) Figures show anti-EGFP IFN-g+ T cell
responses in the spleen detected by ELISpot stimulating
with EGFP PepMix (C) or EGFP200-208 (D) following i.n.
vaccination, using identical vaccines as described above,
administered in a 50-mL volume. Line indicates median (n =
5mice/group). (E–J) Ag-specific T cell responses in the lung
(E–G) and BAL (H–J) were quantified using cell surface
staining with ICS by flow cytometry. Cells were stimulated
with a peptide pool spanning the entire EGFP Ag (EGFP
PepMix), DMSO (negative control), or PMA/ionomycin
(positive control). Legend indicates cytokine-secreting cells
as a percentage of total, live CD8+ T cells. CD4+ responses
were below the limit of detection for all cytokines analyzed
(data not shown). Solid lines indicates geometric mean and
represent n = 3–5 mice/group for lung and BAL, with the
exception of n = 1 for BAL PBS due the low numbers of
cells present in the BAL of PBS-treated mice. The lower
limit of detection frequency was determined by the equa-
tion: [(1/minimum CD8+ count across DMSO and GFP
stimulations)  100]. Statistical significance was deter-
mined using a non-parametric Kruskal-Wallis test with a
post hoc Dunn’s multiple comparison test. *p < 0.05, NS =
p > 0.05. IFN-g, interferon-g; ELISpot, enzyme-linked im-
munospot assay; SFU, spot forming unit; DMSO, dimethyl
sulfoxide, PMA, phorbol 12-myristate 13-acetate; LLD,
lower limit of detection.
Molecular Therapy: Methods & Clinical Developmentcontribute to these inherent differences in immunogenicity are
not conclusive, but it is considered that a combination of factors
could affect the differential immunogenicity of various Ad vectors.
These factors include (1) differences in receptor, co-receptor,
and/or in vivo tissue tropism;1,31,67 (2) the efﬁciency of viral uncoating
and trafﬁcking to the nucleus;30,68,69 (3) the route of vaccine admin-
istration;57 (4) differences in the innate immune sensing of Ad parti-
cles30; as well as (5) the level and persistence of Ag following Ad
vaccination.20,47,48,64,70
The receptor usage and in vitro entry mechanism of Ad5, mediated
via binding to CAR and internalization via cellular integrins, is well
established.71–73 In addition, the in vivo tropism of Ad5 in mice116 Molecular Therapy: Methods & Clinical Development Vol. 16 March 2020following intravenous (i.v.) administration has
been very well studied, and we have substantial
information regarding the interacting cell types
that contribute to immune activation.23,74–78 In
contrast, there is a paucity of information in the
ﬁeld regarding the precise cellular interactionsthat occur following i.m. or i.n. administration with Ad5, and how
these interactions contribute to immunogenicity or protective efﬁ-
cacy.5 Consequently, we have extremely limited insight into how
rare species or non-human Ad vectors engage with speciﬁc APCs
or non-lymphoid cells in vivo at immunological priming sites, and
how these interactions, in conjunction with innate activation, shape
adaptive immune responses.
The in vitro entry receptor for ChAdOx1 has not been characterized.
It has been proposed that it can use CAR, in addition to another as yet
unidentiﬁed receptor on the surface of CHO-K1.1 Evidence suggests
that persistent Ag expression both within draining lymph nodes
(dLNs) and cells within nonlymphoid compartments,20,47 combined
www.moleculartherapy.orgwith minimal induction of innate immunity (namely pathways
driven by type I IFN and/or STING signaling),30,56 are deﬁning char-
acteristics of potently immunogenic Ad vectors.30,79 In support of
this, it has been shown that Ad5 expresses transgene Ag more efﬁ-
ciently in dLNs than does ChAdOx1 following i.m. vaccination,1
potentially offering an explanation for the increased immunogenicity
of Ad5 relative to ChAdOx1. As a result, future studies that aim to
comprehensively characterize the basic biology of rare species or
non-human Ad vectors will be invaluable in deciphering the underly-
ing mechanisms and interactions that result in robust immunoge-
nicity.67 The identiﬁcation of deﬁned entry receptors, the character-
ization of Ad virion pathogen-associated molecular patterns
(PAMPs) that trigger differential innate signaling pathways, as well
as determining the factors that contribute to sustained transgene
expression in vivo will enable genetic engineering of optimal platform
vectors that elicit a distinct phenotype of protective immunity,
tailored to speciﬁc disease targets.
Nonetheless, in the absence of detailed information regarding the
in vivo kinetics of novel Ad platforms, alternative efforts are
currently being undertaken to improve the immunogenicity of exist-
ing Ad vectors. One way this can be achieved is through the incor-
poration of genetic adjuvants to increase immune stimulation,80,81
or recognition of the transgene Ag delivered by a non-replicating
Ad vector. In this study, we have taken an approach to increase
the dissemination of transgene Ag encoded within non-replicating
Ad vectors (i.e., EGFP) to improve immune recognition and, subse-
quently, Ag-speciﬁc immune responses. The previously described
exosome display approach involves the Velcro-like tethering of Ag
to the surface of host-derived EVs/exosomes,37 which we validated
in vitro using a model Ag, EGFP. However, by using non-replicating
Ad vectors to deliver and express the exosome-targeted EGFP_C1C2
and non-targeted control Ag cassettes in vivo, we anticipated that
exosome tethering of EGFP could take place following vaccination.
In this scenario, EGFP would be expressed within cells that take
up the Ad vaccine following immunization, and expressed Ag would
be processed through classical major histocompatibility complex
(MHC) I presentation pathways, resulting in potent CD8+ T cell re-
sponses. However, exosome surface-bound EGFP_C1C2 could also
be released from host cells and taken up by neighboring APCs,
thus creating multiple waves of immune stimulation and potentially
augmenting humoral and cellular immunogenicity. We hypothesized
that this increased Ag dissemination could be used as a general
approach to improve the potency of ChAd, which has weaker immu-
nogenicity than does Ad5.
We conﬁrmed that this approach increased humoral immune re-
sponses in serum following vaccination, without negatively impacting
the potency of cellular immunity. Importantly, the adjuvanting effects
were observed following i.m. and i.n. vaccination, for both Ad5 and
ChAd, and differences were maintained 28 days following immuniza-
tion. Many Ad vectors are being investigated for mucosal delivery to
provide protection against respiratory pathogens,49,61 including in the
development of inﬂuenza virus vaccines.60,82 Ideally, such a vaccineMolecularshould elicit high levels of cross-reactive Ab and T cell responses
following a single vaccination. Recombinant Ad vectors are very
well suited to the development of a universal inﬂuenza virus vaccine,
due to their egg-independent production, rapid manufacturing
capacity, thermostability, and safety in young, old and immunocom-
promised individuals.5,15 With this in mind, we conﬁrmed that both
systemic (serum) and mucosal (BAL) IgG responses were substan-
tially improved following i.n. vaccination for both Ad5 and ChAd
vectors when EGFP was fused to C1C2 (D14 and D28). Importantly,
we determined that these Ab responses displayed a predominantly
IgG2a response in mice. In the context of inﬂuenza virus, Abs of
this subclass which recognize conserved epitopes on the stalk domain
of hemagglutinin (HA), have been shown to play a crucial role in
providing Fc-mediated protection from inﬂuenza virus challenge
through effector function-based clearance mechanisms.50–52 There-
fore, our data suggest that combining an inﬂuenza virus, exosome
display fusion Ag with Ad-mediated vaccination in the future may
increase the magnitude of Ag-speciﬁc responses and enhance protec-
tive efﬁcacy. Increases in the magnitude of the Ab response could
be exploited to maximize immunogenicity in speciﬁc populations,
such as the elderly, in which immunosenescence is known to nega-
tively impact vaccine effectiveness.83,84 Improvements in immuno-
logical potency could also permit Ad vector dose sparing,79 leading
to reduced manufacturing costs and increased availability of vaccine
doses during a pandemic.
As stated, recombinant Ad vectors represent a promising platform for
development, as vaccines for infectious diseases and are increasingly
undergoing clinical evaluation.85 A large number of human and
non-human Ad serotypes with low seroprevalence in humans are
available. This could facilitate their use in heterologous prime-boost
or sequential immunization vaccination regimens, thereby bypassing
issues related to pre-existing Ad immunity. This emphasizes the
importance of continuing to evaluate and develop novel Ad vectors
as a plug-and-play, easily customizable vaccine platform.
In this study, we have shown that fusion of model Ag EGFP to the
C1C2 domain of lactadherin can dramatically improve the humoral
immune responses of a chimpanzee Ad vector, ChAdOx1, an Ad
platform that is currently being evaluated in phase I human clinical
testing.6,7 The increased immunogenicity we observed for ChAd-
EGFP_C1C2 resulted in serum Ab and mucosal (i.e., BAL) responses
that were comparable to, or better than, the potently immunogenic
Ad5 vector (EGFPD), following both i.m. and i.n. vaccination. We
also observed no impairment to CD8+ T cell responses, and noted
improvements in cellular immune responses elicited by ChAd in
the lung, when EGFP was fused to C1C2. These data represent the
ﬁrst report of using the exosome display molecular adjuvant
approach to improve the immunogenicity of a non-human ChAd
(or any non-Ad5-based) vector. Therefore, this strategy could
represent a general approach to improve the immunogenicity of
other rare species or non-human Ad vectors that have weak humoral
immunogenicity, but otherwise desirable stability and manufacturing
characteristics.Therapy: Methods & Clinical Development Vol. 16 March 2020 117
Molecular Therapy: Methods & Clinical DevelopmentMATERIALS AND METHODS
Plasmid Construction and DNA Cloning
An expression plasmid containing the lipid-binding C1C2 domain
of lactadherin Mfge8 and a C-terminal 6XHIS tag, pcDNA3.1-
SS_C1C2,37,39–41,86 was kindly provided by Dr. Clotilde Théry
(INSERM, France). EGFP was ampliﬁed from pEGFP-C1 (Clontech)
by PCRusing primers to introduce engineered restriction sitesHindIII
at the 50 terminus and AgeI-HindIII at the 30 terminus. PCR
fragments were digested with HindIII or AgeI/HindIII and ligated
into HindIII-digested pcDNA3.1-SS_C1C2 to generate the C1C2-
fusion construct pcDNA3.1-SS-EGFP_C1C2, or AgeI/HindIII-di-
gested pcDNA3.1-SS_C1C2 to generate C1C2-deleted pcDNA3.1-
SS-EGFPD (Figure 1A).Adenovirus Genome Engineering and Vaccine Production
In order to facilitate the subsequent generation of recombinant Ad
vectors for Ad5 and chimpanzee adenovirus ChAdOx16,32 genomes
encoding C1C2-fusion EGFP (EGFP_C1C2) and controls lacking
the C1C2 domain (EGFPD), silent mutations were introduced to re-
move existing PmeI and PacI sites in the signal sequence (SS) within
pcDNA3.1-SS-EGFP constructs to create pcDNA3.1-SSmut deriva-
tives. The entire Ag cassette was then ampliﬁed by PCR to introduce
terminal NotI restriction sites and the Ag fragment was cloned into
NotI-digested entry vector (pENTR4) for subsequent homologous
recombination with E1/E3-deleted Ad backbones using Gateway
technology (Life Technologies, Carlsbad, CA, USA), as previously
described.32 Adenoviruses were linearized by PacI/PmeI to release
the infectious viral genome (Ad5/ChAd) and transfected into
TRex293 cells. Viruses were ampliﬁed, puriﬁed by two rounds of ce-
sium chloride banding, and titrated at the Jenner Institute Viral Vec-
tor Core Facility (University of Oxford, Oxford, UK), as previously
described.6,32,87 To conﬁrm that transgene expression was compara-
ble between EGFPD and the fusion construct EGFP_C1C2 when ex-
pressed by an Ad vector, A549 or CHO-CAR cells were infected with
each Ad5 or ChAd vector at the same multiplicity of infection (MOI)
of 250 IFU/cell. EGFP expression was quantiﬁed 22 h post-transduc-
tion by ﬂow cytometry (Figures S1A–S1D).Cells and Culture Media
TRex293 cells were grown in high-glucose (4,500 mg/L) Dulbecco’s
modiﬁed Eagle’s medium (DMEM) supplemented with 4 mM
L-glutamine, 1% (v/v) penicillin-streptomycin, and 5 mg/mL blastici-
din. The addition of blasticidin allows silencing of Ag expression
during Ad vaccine production in TRex293 cells (Life Technologies,
Carlsbad, CA, USA). Expi293 cells (Life Technologies, Carlsbad,
CA, USA) were grown in serum-free Expi media according to the
manufacturer’s instructions. A549 cells were obtained from the
American Tissue Culture Collection (ATCC; CCL-185), and CHO-
CAR cells were a gift fromDr. Georges Santis (King’s College London,
London, UK). A549 cells were grown in ATCC-formulated Kaighn’s
modiﬁcation of Ham’s F-12 (F-12K) medium supplemented with
10% (v/v) FBS and 1% (v/v) penicillin-streptomycin. For work
requiring puriﬁcation of EVs from the SN of Ad-infected A549 cells,118 Molecular Therapy: Methods & Clinical Development Vol. 16 MarchF-12K media was made up with exosome-depleted FBS (Thermo
Fisher, Waltham, MA, USA; lot #2094828). CHO-CAR cells were
maintained in high-glucose DMEM supplemented with 10% (v/v)
fetal calf serum, 110 mg/L sodium pyruvate, 4 mM L-glutamine,
and 1% (v/v) penicillin-streptomycin.
Murine splenocytes were cultured in minimum essential medium
with alpha modiﬁcation (a-MEM) supplemented with 10% (v/v)
FBS, 1% (v/v) penicillin-streptomycin, 4 mM L-glutamine, and
50 mM 2-mercaptoethanol for ex vivo IFN-g ELISpot. Roswell Park
Memorial Institute (RPMI) 1640 medium supplemented with 10%
(v/v) FBS, 100 U/mL penicillin, 100 mg/mL streptomycin, and
2mM L-glutamine (denoted R10) was used for preparing murine lym-
phocytes for ﬂow cytometry-based immunology assays (described in
detail below).
Exosome Purification by Ultracentrifugation and Size-Exclusion
Chromatography
To assess the incorporation of the C1C2-fusion Ag into exosomes
in vitro, 100–250 mL of Expi293F cells (2 106 cells/mL) were trans-
fected with 1.375 mg/mL pcDNA3.1-SSmut expression vectors using
4 mg/mL polyethylenimine (PEI), as previously described.88,89 Trans-
fection efﬁciency was evaluated by ﬂow cytometry analysis of EGFP
expression 48–72 h post-transfection, and cell number was recorded
at harvest (Table S1). A sample of the cell lysate was collected for
anti-HIS western blot analysis to conﬁrm protein expression
following transfection (Figure S1A) or as a control for western blots
to detect proteins enriched in, or excluded from, exosomes but pre-
sent in the cell lysate (Figure 1F). 1 107 cells were lysed in 200 mL of
cell lysis buffer (300 mM NaCl, 50 mM Tris, 0.5% Triton X-100, pH
7.4), and then incubated on ice for 20 min before centrifugation at
20,000  g for 20 min at 4C. The cleared cell lysate was collected,
protein concentration was determined by bicinchoninic acid
(BCA) assay, and aliquots were frozen at 20C prior to further
analysis.
EVs were puriﬁed from serum-free conditioned media using a com-
bination of high-speed ultracentrifugation to enrich the exosome
pellet from 250 mL of SN to 1 mL, followed by the use of size-exclu-
sion chromatography columns previously validated for puriﬁcation
of exosomes.42 96 h post-transfection, Expi293F cells were pelleted
by centrifugation at 400  g for 7 min at 4C. SN was transferred
into a new 50-mL conical tube and centrifuged again at 400  g
for 7 min at 4C. SN was again transferred and centrifuged at
2,000  g for 15 min at 4C, and SN was transferred to a new tube
and centrifuged at 10,000  g for 30 min followed by ﬁltration
through a 0.22-mm ﬁlter as previously described90 before being
stored at 80C prior to ultracentrifugation. A Beckman Coulter
Optima LE-80K ultracentrifuge and 70Ti ﬁxed-angle rotor were
pre-chilled to 4C. SNs were divided over 32.4-mL Bell Optiseal
ultracentrifugation tubes and centrifuged at 100,000  g for 1.5 h
at 4C using slow acceleration and deceleration. The exosome pellet
was pooled and resuspended in a ﬁnal volume of 1 mL of low-particle
Dulbecco’s PBS (DPBS) (Lonza, Basel, Switzerland).2020
Table 1. Abs for ELISA and Western Blot
Marker Species Ab Clone Isotype Working Concentration (mg/mL) Stock Concentration (mg/mL) Application Source
CD9 mouse 209306 IgG2b 1.0 0.5 ELISA R&D Systems
CD63 mouse MEM-259 IgG1 1.0 1.0 ELISA Bio-Rad
CD81 mouse 1D6 IgG1 1.0 1.0 ELISA Bio-Rad
EGFP mouse 9F9.9 IgG1 0.4 1.0 ELISA Abcam
Alix mouse G10 IgG1 1.0 0.2 Western blot Santa Cruz
Grp94 rat 9G10 IgG2a 1.0 0.2 Western blot Enzo
6XHIS mouse HIS.H8 IgG2b 0.2 1.0 Western blot Abcam
www.moleculartherapy.orgExo-spin Midi columns (Cell Guidance Systems, St. Louis, MO, USA)
were prepared as described previously42 and loaded with the 1-mL
sample obtained following ultracentrifugation of Expi293F cell SN.
A total of 24 aliquots of 500 mL were collected and analyzed by ELISA
for tetraspanins CD9, CD63, and CD81 and targeted Ag (i.e., EGFP)
on the surface of exosome elution fractions (see Table 1 for Ab infor-
mation). Relevant data from our experiments have been submitted to
the EV-TRACK knowledgebase (EV-TRACK: EV190049),91 and
methodology complies with guidelines for exosome classiﬁcation as
outlined by position papers from the International Society for Extra-
cellular Vesicles.44,45
CD9, CD63, CD81, and Anti-EGFP ELISA
High-protein-binding 96-well plates were incubated overnight at 4C
with 20 mL of each size-exclusion chromatography elution fraction in
quadruplicate (i.e., for CD9, CD63, CD81, and EGFP). The following
day, plates were washed three times with 200 mL of 0.1% (v/v) BSA in
DPBS (without calcium or magnesium) and blocked with 200 mL of
1% (v/v) BSA for 2 h at room temperature (RT). BSA dilutions
were made up with 10 concentrated reagent diluent solution
(R&D Systems,Minneapolis, MN, USA) diluted in DPBS before being
ﬁltered through a 0.1-mm ﬁlter. Plates were incubated with 100 mL of
mouse anti-human CD9/CD63/CD81 or anti-EGFP diluted in DPBS
with 0.1% (v/v) BSA for 2 h at RT. Following washing, 100 mL of
secondary horseradish peroxidase (HRP)-conjugated Ab was added
and plates were incubated at 37C for 1 h. Plates were washed and
development was performed using 100 mL of SigmaFast o-phenylene-
diamine dihydrochloride (OPD) solution and stopped with 50 mL of
3 MHCl (Thermo Fisher Scientiﬁc, Waltham, MA, USA). Plates were
read at 490 nm. Fractions that had high expression of CD9/CD63
and/or CD81 were pooled and aliquoted before being stored at
80C for downstream exosome analysis and validation. A small
aliquot was not frozen and was kept at 4C for quantiﬁcation of pro-
tein content using a BCA assay and for quantiﬁcation of vesicle titer
and particle size using NanoSight (see below). ELISAs for CD9, CD63,
CD81, and EGFP were repeated on puriﬁed preparations in triplicate,
coating plates with 1 mg/well, alongside matched isotype control Abs
(which were used to subtract background, non-speciﬁc staining). Pos-
itive controls for tetraspanins included validated exosomes derived
from Du145 cells (provided by Dr. J. Webber and Prof. A. Clayton,
Cardiff University),92 and the positive control for detection ofMolecularEGFP included wells coated with 1 mg/mL recombinant EGFP protein
(Abcam, Cambridge, UK).
Western Blot
The protein concentrations of cleared lysate and puriﬁed exosomes
were assessed using the Pierce microBCA protein assay kit (Thermo
Fisher, Waltham, MA, USA). Samples (20 mg) were reduced using
6 loading buffer containing dithiothreitol (DTT) and were boiled
at 95C for 10 min. Samples were loaded onto a 10% Mini-Protean
TGX pre-cast gel (Bio-Rad, Hercules, CA, USA), and SDS-PAGE
was performed at 125 V. Proteins were transferred to a 0.2-mm poly-
vinylidene ﬂuoride (PVDF) membrane (Bio-Rad, Hercules, CA,
USA) using the Trans-Blot Turbo transfer system. Following transfer,
the membrane was incubated in blocking buffer (3% BSA in PBS) for
1 h at RT on a shaking platform. After washing three times with PBS
with 0.1% Tween-20 (v/v), the membrane was incubated for 1 h at RT
with 0.2 mg/mL mouse anti-hexahistidine (Abcam, Cambridge, UK),
1 mg/mL rabbit anti-human Grp94 (Enzo, New York, NY, USA), or
1 mg/mL mouse anti-human ALIX (Santa Cruz, Dallas, TX, USA)
diluted in 3% BSA/PBS (Table 1). Following incubation, a 1:3,000
dilution of alkaline phosphatase-conjugated donkey anti-mouse or
donkey anti-rat secondary Ab (Jackson Laboratory, Bar Harbor,
ME, USA) was added for 1 h. The membrane was washed four times
and then incubated with 5-bromo-4-chloro-3-indolyl phosphate
(BCIP)/nitroblue tetrazolium (NBT) substrate (Sigma-Aldrich, St.
Louis, MO, USA) until clear bands developed. The reaction was
stopped using deionized water, and images were scanned and edited
using GIMP 2.10.10 photo editing software to uniformly adjust
brightness/contrast and to crop images for clear visualization.
NTA
The size and concentration of puriﬁed EVs were measured at the
Radcliffe Department of Medicine, University of Oxford, using a
NanoSight NS300 instrument (Malvern Panalytical, Malvern, UK),
sCOMS camera, and NTA software version 2.3, build 0033. Synthetic
100-nm Nanosphere size standard particles (Thermo Fisher Scienti-
ﬁc, Loughborough, UK) were used for calibration. EVs puriﬁed
from 100–250 mL of Expi293F SNs were prepared for NTA analysis
by dilution in nanoparticle-free H2O (Fresenius Kabi, Runcorn, UK).
Dilutions ranging from 1:100 to 1:1,000 were performed so that more
than 1  108 EVs/mL were being analyzed. Samples were analyzedTherapy: Methods & Clinical Development Vol. 16 March 2020 119
Molecular Therapy: Methods & Clinical Developmentaccording to the following measurement script—prime, 5-s delay,
30-s capture—and measurements were repeated three times per
sample. Camera shutter speed was ﬁxed at 19.97 ms and camera
gain at 300 ms. Ambient temperature was recorded to be 21.8C–
22.8C. Video acquisitions were analyzed using proprietary NTA
software, with minimal expected particle size, minimum track length,
and blur setting set to AUTO.
Expression of Exosome Display EGFP by Ad Vaccines In Vitro
A549 cells were seeded in six-well plates at 0.5  106 cells/well and
allowed to adhere overnight. The following day, serum-containing
F-12K media were removed, cells were washed with PBS, and media
were replaced with 1 mL of serum-free media containing Ad virus at a
MOI of 250 (IFU/cell). Each test was performed in duplicate. Cells
were infected for 3 h at 37C, after which the virus suspension was
removed and media were replaced with 5 mL of F-12K containing
10% exosome-depleted FBS (Thermo Fisher, Waltham, MA, USA).
The Ad infection was allowed to proceed for 72 h, after which the
cell SNs were harvested for puriﬁcation of EVs. The SNs from dupli-
cate wells (5 mL) were combined (10 mL) and pelleted by centrifuga-
tion at 400 g for 7 min at 4C. SN was transferred into a new 50-mL
conical tube and centrifuged again at 400 g for 7 min at 4C. SNwas
again transferred and centrifuged at 2,000  g for 15 min at 4C,
transferred to a new tube, and centrifuged at 10,000  g for
30 min, followed by ﬁltration through a 0.22-mm ﬁlter. The ﬁltered
10 mL of SN was then added to 5 mL of total exosome isolation re-
agent (Thermo Fisher, Waltham, MA, USA), and the suspension
was mixed by vortexing and incubated overnight at 4C to allow pre-
cipitation of vesicles. The following day, SN samples were pelleted by
centrifugation at 10,000  g for 1 h at 4C, after which the pellet was
resuspended in 250 mL of DPBS, as above. Protein concentration was
determined using the Pierce microBCA protein assay kit (Thermo
Fisher, Waltham, MA, USA). Exosome ELISA assays to quantify
CD9, CD63, CD81, and exosome display EGFP were performed
exactly as described above with the exception that 4 mg/well puriﬁed
exosomes was used to coat ELISA plates (Figure S2).
Mice and Vaccination
All animal studies were approved by the Icahn School of Medicine at
Mount Sinai Institutional Animal Care and Use Committee (IACUC-
2017-0170). Animal studies adhere to the ARRIVE guidelines.93 Fe-
male BALB/cJ mice (Jackson Laboratory, Bar Harbor, ME, USA)
aged 6–8 weeks (n = 5–10 mice/group) received 108 IFU87 of a
non-replicating Ad vaccine vector diluted in sterile PBS, administered
either i.m. or i.n. in a total volume of 50 mL. Control animals received
50 mL of PBS (Life Technologies, Carlsbad, CA, USA). For i.n. vacci-
nations, mice were anesthetized i.m. using ketamine and xylazine
diluted in water for injection (WFI; Thermo Fisher Scientiﬁc, Wal-
tham, MA, USA). A pre-vaccination blood sample was obtained
from each animal by submandibular bleeding at least 2 days prior
to vaccination (day 2). Maximal blood sampling throughout the
duration of the experiment did not exceed recommended guidelines
per total blood volume (TBV), as established by the National Centre
for the Replacement, Reﬁnement and Reduction of Animals in120 Molecular Therapy: Methods & Clinical Development Vol. 16 MarchResearch (NC3Rs): a maximum of <10% on any single occasion
and <15% TBV within 28 days. Two to four weeks (D14 or D28) later,
mice were euthanized by increasing CO2 concentration, death was
conﬁrmed by cervical dislocation, and serum and/or spleens were
collected for analysis of humoral and cellular immunogenicity. We
also collected the BAL ﬂuid and lungs of mice vaccinated i.n, for
analysis of mucosal immune responses. The latter mice were eutha-
nized by increasing CO2 concentration, followed by exsanguination
rather than cervical dislocation, to facilitate collection of BAL ﬂuid
without disruption of the trachea.
Quantification of EGFP IgG Ab Responses
To measure total Ag-speciﬁc IgG responses following vaccination,
Immulon 4HBX ﬂat-bottom 96-well plates (Thermo Fisher Scientiﬁc,
Waltham, MA, USA) were coated overnight at 4C with recombinant
EGFP protein at 1 mg/mL (Abcam, Cambridge, UK) diluted in 50 mL
of 50 mM carbonate Na2CO3 buffer (Sigma-Aldrich, St. Louis, MO,
USA). The following day, plates were washed using 1 PBS (Life
Technologies, Carlsbad, CA, USA) containing 0.1% (v/v) Tween 20
(Millipore, Burlington, MA, USA) and subsequently blocked with
200 mL of blocking buffer, PBS containing 1% (w/v) BSA (Sigma-
Aldrich, St. Louis, MO), for at least 1 h at RT to reduce non-speciﬁc
binding. After washing, a 1:100 dilution of mouse sera was added to
the plate in duplicate, a 3-fold serial dilution in blocking buffer was
performed (ﬁnal volume, 100 mL), and plates were incubated for
2 h at RT on an orbital shaker. A mouse monoclonal Ab to EGFP
(Abcam, Cambridge, UK) was used as a positive control, and an iso-
type control (mouse monoclonal IgG1; Abcam, Cambridge, UK) was
used as a negative control. Additional controls included naive unvac-
cinated mouse sera and secondary Ab-only controls. After washing,
100 mL of goat anti-mouse IgG HRP-conjugated secondary Ab (Milli-
pore, Burlington, MA, USA) diluted 1:5,000 in blocking buffer was
added to the plate. After a 1-h incubation at 37C, the plate was
washed and developed using 100 mL of SigmaFast OPD (Sigma-
Aldrich, St. Louis, MO, USA) tablets diluted in water and stopped
with 50 mL of 3 M HCl. Plates were read at 490 nm. Baseline was
deﬁned as the mean response of naive sera plus 3 times the standard
deviation (SD) of the mean optical density (OD) values. Endpoint ti-
ters were calculated using GraphPad Prism v8.2.1 and represent the x
intercept with the baseline (mean of naive sera at 1:100 dilution + 3
times the SD). Values below the limit of detection were estimated
to be at half the input dilution. The AUC was calculated in GraphPad
Prism v8.2.1 and represents the total peak area, where baseline was set
as described above, and was <10% of the y axis minimum to
maximum value. When AUC values could not be calculated, an arbi-
trary value of 1.0 was assigned. Naive sera controls, in addition to a
positive control Ab (i.e., mouse anti-EGFP) with matched isotype
control, were run on every ELISA plate for quality control.
Anti-EGFP IgG Subclass ELISA
To measure Ag-speciﬁc responses across multiple IgG subclasses
following vaccination, ELISAs were performed as above with the
following modiﬁcations. Following incubation with serial dilutions
of vaccinated mouse sera starting at 1:33.3–1:100, or control sera/Abs,2020
www.moleculartherapy.org50 mL of biotin-conjugated secondary rat Abs speciﬁc for each
IgG subclass, i.e., anti-mouse IgG1 (BD Biosciences, Franklin Lakes,
NJ, USA), anti-mouse IgG2a (BD Biosciences, Franklin Lakes, NJ,
USA), and anti-mouse IgG2b (BD Biosciences, Franklin Lakes, NJ,
USA), were diluted to 1 mg/mL in blocking buffer and added to the
plate. After a 1 h incubation shaking at RT, 50 mL of ExtrAvidin-
peroxidase (Sigma-Aldrich, St. Louis, MO, USA) diluted 1:2,500 in
blocking buffer was added to each well and incubated for 30 min at
RT. Plates were washed prior to development and analysis, exactly
as described above.
Quantification of Spleen ELISpot Responses to Vaccination
EGFP-speciﬁc IFN-g-producing cells were quantiﬁed using a murine
ELISpot kit (Mabtech, Nacka Strand, Sweden). 96-well PVDF plates
(Millipore, Burlington, MA, USA) were pre-coated with 5 mg/mL
rat anti-mouse IFN-g capture Ab (clone AN18: Mabtech, Nacka
Strand, Sweden) 24–48 h prior to performing the ELISpot. Spleens
were homogenized manually through a 40-mm cell strainer, and red
blood cells were lysed by incubation for 5 min in ammonium-chlo-
ride-potassium (ACK) lysis buffer (0.15 M NH4Cl, 10 mM KHCO3,
100 mM EDTA-Na2 diluted in water). Splenocytes were resuspended
at 106 cells/mL in complete a-MEM. A range of dilutions for the input
cell number per well was tested, ranging from 1.25 to 5.0  105 cells/
well. Samples were analyzed in triplicate for each mouse in a ﬁnal vol-
ume of 100 mL. Splenocytes were stimulated with EGFP PepMix, a
pool of 57 peptides (15-mer peptides overlapping by 11 aa) spanning
the full length of EGFP (JPT Peptides, Berlin, Germany), or with
EGFP200–208 (HYLSTQSAL), a H2-Kd-restricted CD8
+ T cell epitope
(JPT, Berlin, Germany), at a ﬁnal individual peptide concentration of
1 mg/mL. Stimulated splenocytes were incubated at 37Cwith 5%CO2
for 18–20 h. Controls included cells stimulated with concanavalin A
from Canavalia ensiformis (ConA; Sigma-Aldrich, St. Louis, MO,
USA) at a ﬁnal concentration of 5 mg/mL as a positive control, or
a-MEM media alone as an unstimulated control. Following incuba-
tion, plates were washed with PBS to remove cells and incubated
with biotinylated rat anti-mouse IFN-g (Mabtech, Nacka Strand,
Sweden) diluted to 1 mg/mL in PBS for 2–4 h at RT. Streptavidin-con-
jugated alkaline phosphatase (Mabtech, Nacka Strand, Sweden)
diluted to 1 mg/mL in PBS was added directly to the plates for 1 h
at RT. The plates were washed six times with PBS and responses
were detected using an alkaline phosphatase development buffer
(Bio-Rad, Hercules, CA, USA). The ELISpot plates were dried before
quantiﬁcation of spots using an AID ELISpot reader (AID Diagnos-
tika, Strassberg, Germany). Results were expressed as spot-forming
units (SFU) per million splenocytes and were calculated by subtract-
ing the mean negative control response from the mean peptide
response. Responses in negative control wells were <30 SFU/106
splenocytes, and positive control wells (ConA) displayed >500
SFU/106 splenocytes.
Lung Processing and Flow Cytometry with ICS
Mice were humanely euthanized with an increasing concentration of
CO2, followed by exsanguination by severing the femoral artery. BAL
was obtained from the lung using a 2 mL PBS wash. BAL cell samplesMolecularwere pelleted by centrifugation (500 g, 5 min), and SNwas collected
for ELISAs. The cell pellet was resuspended in 500 mL of RBC lysis
buffer (QIAGEN, Hilden, Germany) for 5 min, then washed in
5 mL of R10 media.
Following collection of BAL, lungs were subsequently perfused with
1 mL of PBS by cardiac puncture, then dissected into 5 mL of diges-
tionmedia (1.5%CaCl2, 1% FBS, 30 mg/mLDNase I, 0.7 mg/mL colla-
genase type IV in distilled H2O [dH2O]) in C Tubes (Miltenyi Biotec,
Bergisch Gladbach, Germany) on ice. Lungs were homogenized using
a gentleMACS dissociator (Miltenyi Biotec, Bergisch Gladbach, Ger-
many) and placed in a shaking incubator at 37C for 45–60 min. The
lung homogenate was ﬁltered through a 100-mm sieve, pelleted by
centrifugation (300 g, 8 min), and resuspended in 5mL of RBC lysis
buffer for 5 min. Lung homogenate was washed through a 40-mm
sieve using 10 mL of R10 and then pelleted by centrifugation. Cells
from BAL and perfused lungs were resuspended in R10 media con-
taining anti-mouse CD28 (1:1,000, BD Biosciences, Franklin Lakes,
NJ, USA), brefeldin A (1:1,000, BD Biosciences, Franklin Lakes,
NJ), and monensin (1:1,000, BD Biosciences, Franklin Lakes, NJ,
USA). Cells from BAL and lung were stimulated for 6 h at 37C in
5% CO2 with either 1 mg/mL EGFP PepMix, an equivalent volume
of DMSO as a negative control, or a positive control stimulation cock-
tail containing phorbol 12-myristate 13-acetate (PMA; 0.5 mg/mL,
Sigma-Aldrich, St. Louis, MO, USA) and ionomycin (1 mg/mL,
Sigma-Aldrich, St. Louis, MO, USA). After stimulation, cells were
washed in FACS buffer (PBS containing 0.1% BSA and 2 mM
EDTA; 500  g for 5 min) and incubated with Fc block (1:100,
eBioscience, Thermo Fisher Scientiﬁc, Waltham, MA, USA) for
10 min at 4C. Cells were washed in FACS buffer and incubated
with surface staining cocktail for 30 min at 4C (see Table 2). Cells
were washed in FACS buffer and then incubated in ﬁxation/permea-
bilization buffer (BD Biosciences, Franklin Lakes, NJ, USA) for
10 min at 4C. Cells were washed in 1 permeabilization buffer
(BD Biosciences), then incubated with the intracellular staining
cocktail for 30 min at 4C (see Table 2). Samples were washed in
1 permeabilization buffer and then FACS buffer and resuspended
in FACS buffer for acquisition. Samples were acquired on an LSR II
cytometer (BD Biosciences, Franklin Lakes, NJ, USA) using
FACSDiva v7.03 (BD Biosciences, Franklin Lakes, NJ, USA), with
the relevant single ﬂuorochrome compensation controls and photon
multiplier tube voltages set by daily acquisition of Cytometer Setup
and Tracking beads (BD Biosciences, Franklin Lakes, NJ, USA).
FACS Analysis
The transduction efﬁciency and comparable transgene expression of
Ad vectors Ad5- and ChAd- expressing EGFPD and EGFP_C1C2
were conﬁrmed by ﬂow cytometry, exactly as described previously94
(Figures S1B–S1E). Samples were acquired using an LSR II (BD Bio-
sciences, San Jose, CA, USA) acquiring >20,000 gated events, and
analysis was performed using FlowJo v10.4.2 (Tree Star, Ashland,
OR, USA). The relative ﬂuorescence intensity (RFI) was calculated
by multiplying the percentage of EGFP-positive cells by the geometric
mean ﬂuorescence intensity.Therapy: Methods & Clinical Development Vol. 16 March 2020 121
Table 2. Abs for Flow Cytometry
Marker Staining Cocktail Fluorochrome Ab Clone Dilution Stock Concentration (mg/mL) Source
CD3 surface Paciﬁc Blue 17A2 1 in 100 0.5 BioLegend
CD4 surface Brilliant Violet 510 RM4-5 1 in 150 0.2 BioLegend
CD8 surface Alexa Fluor 700 53-6.7 1 in 50 0.2 eBioscience
LIVE/DEAD surface Near Infrared N/A 1 in 1,000 N/A Thermo Fisher
IL-2 intracellular PE-Cy7 JES6-5H4 1 in 250 0.2 eBioscience
IFN-g intracellular eFluor 660 XMG1.2 1 in 500 0.2 eBioscience
TNF-a intracellular Alexa Fluor 488 MP6-XT22 1 in 2,000 0.5 eBioscience
N/A, not applicable; PE, phycoerythrin.
Molecular Therapy: Methods & Clinical DevelopmentFor the detection of cellular immune responses by ICS, >24,000 CD4+
and >3,800 CD8+ T cells were acquired on lung lymphocyte test
samples, and >360 CD4+ and >160 CD8+ T cells were acquired on
BAL test samples. Data were analyzed using FlowJo software to gate
on size, singlets, live cells, CD3+, and then CD4+ or CD8+, and then
assessed for IFN-g, IL-2, and TNF-a secretion (see Figure S5 for
gating strategy). Autologous unstimulated (DMSO) responses were
subtracted from EGFP-stimulated responses for lung lymphocytes.
BAL samples were gated using an identical gating strategy and the
mean cytokine frequency of two representative unstimulated
(DMSO) BAL samples subtracted from each EGFP-stimulated sam-
ple. Lung lymphocytes and BAL PMA/ionomycin-stimulated samples
passed a >1% cytokine response positive control threshold. All BAL
samples passed negative quality control. Two lung samples did not
pass negative quality control and were excluded from the analysis.Statistical Analyses and Data Analysis Software
Differences between each Ad-vaccinated group (D versus C1C2) were
calculated using the non-parametric Mann-Whitney test. For lung
and BAL ICS analyses, a Kruskal-Wallis test with Dunn’s correction
for multiple comparisons was used to compare EGFPD, EGFP_C1C2,
and PBS control groups. Statistical signiﬁcance was determined to be
*p < 0.05, **p < 0.01, ***p < 0.001, or ****p < 0.0001. Data were
graphed using GraphPad Prism v8.2.1 (GraphPad, San Diego, CA,
USA). Flow cytometry data were analyzed using FlowJo v10.4.2
(Tree Star, Ashland, OR, USA).SUPPLEMENTAL INFORMATION
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